Phase I Study of Anti–Epidermal Growth Factor Receptor Antibody Cetuximab in Combination With Radiation Therapy in Patients With Advanced Head and Neck Cancer - Concepedia

Concepedia

Publication | Closed Access

Phase I Study of Anti–Epidermal Growth Factor Receptor Antibody Cetuximab in Combination With Radiation Therapy in Patients With Advanced Head and Neck Cancer

473

Citations

38

References

2001

Year

Francisco Robert, Mark P. Ezekiel, Sharon A. Spencer, Ruby F. Meredith, James A. Bonner, M.B. Khazaeli, Mansoor N. Saleh, Delicia Carey, Albert F. LoBuglio, Richard Wheeler,

Journal of Clinical Oncology

Abstract

Cetuximab can be safely administered with RT. The recommended dose for phase II/III studies is a loading dose of 400 to 500 mg/m(2) and a maintenance weekly dose of 250 mg/m(2).

References

	Year	Citations

Page 1